Jan Dominik Kuhlmann
Overview
Explore the profile of Jan Dominik Kuhlmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwarz F, Klotz D, Yang R, Brux M, Buchholz F, Harb H, et al.
Cancer Gene Ther
. 2025 Feb;
PMID: 39915607
PARP-inhibitors (PARPi) are an integral part of ovarian cancer treatment. However, overcoming acquired PARPi resistance or increasing the benefit of PARPi in patients without homologous recombination deficiency (HRD) remains an...
2.
Schwarz F, Kuhlmann J, Kampfer J, Klimova A, Klotz D, Freitag L, et al.
Mol Cancer
. 2024 Aug;
23(1):174.
PMID: 39180062
The drug efflux transporter P-glycoprotein, encoded by the ABCB1 gene, promotes acquired chemoresistance. We explored the presence and clinical relevance of circulating cell-free ABCB1 transcripts (cfABCB1) in ovarian cancer patients...
3.
Schwarz F, Klotz D, Wimberger P, Kuhlmann J
Front Oncol
. 2024 Jul;
14:1392545.
PMID: 39077473
Objectives: We have recently described a predictive/prognostic model for ovarian cancer, exploiting commonly available clinico-pathological parameters and the ovarian serum biomarkers mesothelin (MSL), human epididymis protein 4 (HE4) and cancer-antigen...
4.
Kutz O, Drukewitz S, Kruger A, Aust D, William D, Oster S, et al.
Clin Chem Lab Med
. 2024 Apr;
62(10):2070-2081.
PMID: 38577791
Objectives: We analysed whether temporal heterogeneity of ctDNA encodes evolutionary patterns in ovarian cancer. Methods: Targeted sequencing of 275 cancer-associated genes was performed in a primary tumor biopsy and in...
5.
Klotz D, Link T, Wimberger P, Kuhlmann J
Clin Chem Lab Med
. 2023 Oct;
62(3):530-539.
PMID: 37816681
Objectives: Numerous prognostic models have been proposed for ovarian cancer, extending from single serological factors to complex gene-expression signatures. Nonetheless, these models have not been routinely translated into clinical practice....
6.
Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4606-4612.
PMID: 37725572
Purpose: The GeparX study investigated whether denosumab as add-on treatment to nab-paclitaxel-based neoadjuvant chemotherapy (NACT) with two different schedules (125 mg/m² weekly vs. day 1, 8 every 22 days) may...
7.
Wetzk M, Grubling N, Forberger A, Klengel J, Kuhlmann J, Wimberger P, et al.
Geburtshilfe Frauenheilkd
. 2023 Aug;
83(8):1043.
PMID: 37588257
[This corrects the article DOI: 10.1055/a-1580-0601.].
8.
Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
Klotz D, Schwarz F, Dubrovska A, Schuster K, Theis M, Kruger A, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568590
Overcoming PARPi resistance is a high clinical priority. We established and characterized comparative in vitro models of acquired PARPi resistance, derived from either a -proficient or -deficient isogenic background by...
9.
Wimberger P, Blohmer J, Krabisch P, Link T, Just M, Sinn B, et al.
Breast Cancer Res
. 2023 Mar;
25(1):32.
PMID: 36978142
Background: Disseminated tumor cells (DTCs) in the bone marrow are observed in about 40% at primary diagnosis of breast cancer and predict poor survival. While anti-resorptive therapy with bisphosphonates was...
10.
Arndt C, Tunger A, Wehner R, Rothe R, Kourtellari E, Luttosch S, et al.
Front Pharmacol
. 2023 Feb;
14:970457.
PMID: 36817127
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human...